ABUS (Arbutus Biopharma) Shiller PE Ratio: (As of Sep. 06, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ABUS Arbutus Biopharma Corp ABUS
52 GF Score
Price $5.15
GF Value $49.20
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Arbutus Biopharma Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Arbutus Biopharma  (NAS:ABUS) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Arbutus Biopharma Shiller PE Ratio Related Terms


Arbutus Biopharma Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Arbutus Biopharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arbutus Biopharma Shiller PE Ratio Chart

Arbutus Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Arbutus Biopharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ABUS vs CADL, WVE, IMMX: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Arbutus Biopharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arbutus Biopharma Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Arbutus Biopharma's Shiller PE Ratio falls into.


ABUS
52GF Score
Arbutus Biopharma Corp ABUS
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arbutus Biopharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Arbutus Biopharma's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, Arbutus Biopharma's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.03/333.9520*333.9520
=-0.030

Current CPI (Jun. 2026) = 333.9520.

Arbutus Biopharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 -0.370 241.428 -0.512
201612 -4.090 241.432 -5.657
201703 -0.340 243.801 -0.466
201706 -0.330 244.955 -0.450
201709 -0.210 246.819 -0.284
201712 -0.670 246.524 -0.908
201803 -0.360 249.554 -0.482
201806 0.010 251.989 0.013
201809 -0.490 252.439 -0.648
201812 -0.370 251.233 -0.492
201903 -0.470 254.202 -0.617
201906 -0.460 256.143 -0.600
201909 -1.500 256.759 -1.951
201912 -0.460 256.974 -0.598
202003 -0.250 258.115 -0.323
202006 -0.250 257.797 -0.324
202009 -0.270 260.280 -0.346
202012 -0.230 260.474 -0.295
202103 -0.210 264.877 -0.265
202106 -0.230 271.696 -0.283
202109 -0.240 274.310 -0.292
202112 -0.150 278.802 -0.180
202203 -0.110 287.504 -0.128
202206 -0.100 296.311 -0.113
202209 -0.120 296.808 -0.135
202212 -0.140 296.797 -0.158
202303 -0.100 301.836 -0.111
202306 -0.100 305.109 -0.109
202309 -0.120 307.789 -0.130
202312 -0.120 306.746 -0.131
202403 -0.100 312.332 -0.107
202406 -0.110 314.175 -0.117
202409 -0.100 315.301 -0.106
202412 -0.070 315.605 -0.074
202503 -0.130 319.799 -0.136
202506 0.010 322.561 0.010
202509 -0.040 324.800 -0.041
202512 -0.010 324.054 -0.010
202603 0.870 330.213 0.880
202606 -0.030 333.952 -0.030

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Arbutus Biopharma (ABUS) Overvalued in 2026?

Based on GuruFocus' analysis, Arbutus Biopharma stock appears to be undervalued. The current stock price of $5.15 is trading 89.5% below its estimated GF Value™ of $49.20. GuruFocus considers Arbutus Biopharma to be Possible Value Trap.

Key valuation signals for ABUS:

  • Shiller PE Ratio:
  • GF Value™: $49.20 vs. price of $5.15 (89.5% below fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the ABUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Arbutus Biopharma Business Description

Other Exchanges I9DN:Germany
Address 701 Veterans Circle, Warminster, PA, USA, 18974
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
52GF Score

Get the complete analysis for ABUS

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.15
Price
$49.20
GF Value